Filing Analysis
Daré Bioscience completed multiple closings of a Regulation A offering between May 1 and May 6, 2026, issuing 195,010 Investor Units at $5.00 per unit. The offering raised approximately $975,050 in gross proceeds and involves the issuance of convertible preferred stock and warrants.
Red Flags
- Potential for significant dilution due to the issuance of convertible preferred stock and double warrants (two warrants per unit).
- Reliance on Regulation A offerings, which are often utilized by micro-cap companies when traditional institutional capital markets are less accessible.
Key Facts
- Closings occurred on May 1, 4, 5, and 6, 2026.
- Issued 195,010 Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two warrants.
- The offering price was $5.00 per Investor Unit.
- A total of 390,020 warrants were issued in connection with these closings.
- The offering is conducted under Regulation A pursuant to an offering statement on Form 1-A qualified on April 1, 2026.
Daré Bioscience updated its corporate presentation on April 22, 2026, and made it available on its investor relations website. The presentation was furnished as an exhibit to provide current information to investors under Regulation FD.
Key Facts
- Updated corporate presentation made available on April 22, 2026
- Information furnished under Item 7.01 Regulation FD Disclosure
- Exhibit 99.1 contains the full presentation dated April 22, 2026
Daré Bioscience completed a closing of its Regulation A offering on April 17, 2026, issuing 20,000 Investor Units at $5.00 per unit. Each unit includes one share of Series A Convertible Preferred Stock and two warrants for common stock.
Red Flags
- Potential for significant dilution from convertible preferred stock and warrants.
- The current closing raised only $100,000, a very small fraction of the $24.27 million maximum offering capacity.
- Reliance on Regulation A offerings often indicates a company is targeting retail investors because institutional capital is less accessible.
Key Facts
- Issued 20,000 Investor Units for total gross proceeds of $100,000 on April 17, 2026.
- Each unit consists of one Series A Convertible Preferred share and two warrants to purchase common stock.
- The offering is part of a larger Regulation A program for up to 4,854,000 units (potential $24.27 million).
- The offering statement was qualified by the SEC on April 1, 2026.
Daré Bioscience rebalanced its staggered Board of Directors by moving Gregory W. Matz from Class II to Class III. This administrative change involved a technical resignation and immediate reappointment to ensure even distribution across board classes.
Key Facts
- The Board of Directors consists of six members divided into three classes.
- Gregory W. Matz resigned as a Class II director on April 16, 2026.
- Mr. Matz was simultaneously reappointed as a Class III director.
- The reclassification was performed to rebalance the board so each class consists of approximately one-third of the total directors.
- Mr. Matz will now stand for re-election at the 2026 annual meeting of stockholders instead of 2028.
Daré Bioscience completed a closing of its Regulation A offering on April 10, 2026, issuing 3,470 Investor Units at $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
Red Flags
- The issuance of convertible preferred stock and warrants is dilutive to existing common stockholders.
- The extremely small size of this specific closing ($17,350) may indicate weak investor demand for the Regulation A offering.
Key Facts
- Completed a closing of a Regulation A offering on April 10, 2026.
- Issued 3,470 Investor Units at a price of $5.00 per unit, totaling $17,350 in this specific closing.
- Each unit includes one share of Series A Convertible Preferred Stock and two warrants (6,940 warrants total).
- The offering is conducted under Form 1-A (File No. 024-12688), qualified by the SEC on April 1, 2026.
- The total offering size is up to 4,854,000 units.
Daré Bioscience, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release furnished on March 26, 2026.
Key Facts
- Financial results for the year ended December 31, 2025 were announced.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release was included as Exhibit 99.1.
- The filing was signed by CEO Sabrina Martucci Johnson.
Daré Bioscience completed a closing of its Regulation A offering on March 16, 2026, issuing 43,050 units at $5.00 per unit. Each unit consists of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
Red Flags
- Dilutive financing structure involving convertible preferred stock and warrants
- Low capital intake in this specific closing ($215,250) relative to the $24.27M offering maximum
Key Facts
- Closed a portion of a Regulation A offering on March 16, 2026
- Issued 43,050 Investor Units at a price of $5.00 per unit
- Gross proceeds from this specific closing totaled approximately $215,250
- Each unit contains one share of Series A Convertible Preferred Stock and two warrants (86,100 warrants total in this closing)
- The total offering is for up to 4,854,000 units (approximately $24.27 million maximum)
- The offering statement on Form 1-A was qualified by the SEC on January 5, 2026
Daré Bioscience completed the second closing of its Regulation A offering on March 6, 2026, raising approximately $87,500. The company issued 17,500 units, each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock.
Key Facts
- Closing date: March 6, 2026
- Units issued in this closing: 17,500
- Offering price: $5.00 per unit
- Total warrants issued in this closing: 35,000
- The offering is part of a larger Regulation A offering of up to 4,854,000 units
- Each unit contains one share of Series A Convertible Preferred Stock and two warrants
Daré Bioscience, Inc. updated its corporate presentation on March 2, 2026, and made it available on its investor relations website. The presentation is furnished as an exhibit to the 8-K filing under Regulation FD.
Key Facts
- Updated corporate presentation released on March 2, 2026.
- Presentation is available on the company's website at https://ir.darebioscience.com.
- The filing is furnished under Item 7.01 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.